Neurogene NGNE
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 35th percentile, 5-year average -4.4x
Near the top of its 5-year range · 83rd percentile, 5-year average 1.2x
#3447 of 5311 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 93rd percentile, 5-year average 191.6x
#5061 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.54 | – | 1.16 | 83% (pricier than usual) | #3447 of 5311 (1 = cheapest) |
| PE | -5.47 | -4.00 | -4.36 | 35% (cheaper than usual) | – |
| PS | 596.01 | – | 191.59 | 93% (pricier than usual) | #5061 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on NGNE.
Sign in to join the discussion.